DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)

Information source: Charite University, Berlin, Germany
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infection Resistant to Multiple Drugs

Intervention: TDM, Monitoring of Neuro-and Nephropathology (Other)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Charite University, Berlin, Germany

Official(s) and/or principal investigator(s):
Maria Deja, Prof., Principal Investigator, Affiliation: Charité Universititaetsmedizin Berlin

Summary

Multi-Drug resistant pathogens (MDR) are reported worldwide with increasing incidence, especially in intensive care settings. One of the drugs which are effective against MDRs, is colistin (polymyxin E). This agent has been reintroduced in response to the increase of MDR pathogens and might be used more often in the future. Data on safety regarding the most important side effects are not sufficiently available. l This study evaluates the toxicity in patients who receive aerosolized colistin.

Clinical Details

Official title: Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Number and frequency of adverse events (nephro- or neurotoxicity after aerosolised colistin therapy)

Secondary outcome:

Serum concentration of colistin and β-Lactam antibiotics

Serum levels of colistin and β-Lactam antibiotics (e.g. Meropenem)in mg/L

Detailed description: There is growing evidence that patients in the ICU setting have a special risk profile for consecutive colonization and possible infection due to MDR pathogens. One therapy option is the use of inhalative colistin, as this agent has been demonstrated to

be effective against these pathogens. Data on pharmacodynamics or - kinetics are transferred

from older studies or from other patient populations. For patients with pulmonary colonization or infection due to an MDR pathogen the systemic resorption of the drug is not known, consequently systemic side effects including kidney or neural damage are not predictable. This study focus on patients with inhalative colistin therapy and uses therapeutic drug monitoring to determine the rate of systemic resorption of colistin. For the evaluation of neurotoxicity function of peripheral nerves (neve conduction velocity) and of the eighth cranial nerve is monitored. Nephrotoxicity is estimated by creatinine level (-clearance) and the RIFLE criteria.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion criteria:

- invasive ventilated patients (male and female) with assumed or assured bacteria with

an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection

- indicated colistin co-therapy or eradication-attempt with inhalative colistin

(β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital Exclusion criteria:

- Consent of the patient or of the patient´s legal representative can´t be obtained

soon

- Age < 18 years

- Included within another, prospective clinical antibiotics-study

- Hypersensitivity to colistin or polymyxin B

- Patients with cystic fibrosis

- Present letter of attorney or patient´s provision, which precludes a priori the

participation in studies

- Missing consent for storage of pseudonymized data in context of the study

- The patient is in an institution due to a court injunction or administrative order

Locations and Contacts

Charité Universitätsmedizin Charité, Berlin 13353, Germany
Additional Information

This study initiative is launched by the ABx study group.

Related publications:

Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med. 2009 May;103(5):707-13. doi: 10.1016/j.rmed.2008.11.018. Epub 2008 Dec 31.

Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis. 2009 Jun 15;48(12):1729-31. doi: 10.1086/599226.

Michalopoulos AS, Karatza DC. Multidrug-resistant Gram-negative infections: the use of colistin. Expert Rev Anti Infect Ther. 2010 Sep;8(9):1009-17. doi: 10.1586/eri.10.88. Review.

Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med. 2000 Jul;162(1):328-30.

Starting date: September 2013
Last updated: April 8, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017